Brief: Avacta says AVA6103 drug candidate achieves proof of mechanism in Phase 1 trial
16/09/2026 17:36
BRIEF-Avacta says AVA6103 drug candidate achieves proof of mechanism in Phase 1 trial Sept 16 (Reuters) - Avacta Group PLC AVCT.L:
AVACTA ACHIEVES CLINICAL PROOF OF MECHANISM FOR THE NEXT GENERATION OF PRE|CISION® MEDICINES WITH AVA6103 (FAP-EXD) IN THE PHASE 1 FOCUS-01 TRIAL
AVACTA THERAPEUTICS - AVA6103 DEMONSTRATES CLEAN SAFETY PROFILE AT DOSE LEVEL 50% ABOVE MTD OF CONVENTIONAL EXATECAN
AVACTA THERAPEUTICS - FIRST EFFICACY DATA FROM FOCUS-01 TRIAL WITH AVA6103 EXPECTED IN H1 2027
Source text: ID:nGNX1yyJHX
Further company coverage: AVCT.L